Home Insights ISPOR Europe 2022

ISPOR Europe 2022

3 mins read

We’re excited to be attending and presenting at ISPOR Europe November 6—9th. This year’s conference theme is Collaborating Across Borders: Building & Using Evidence to Enable Access. Our HEOR and Market Access experts and colleagues across our Putnam PHMR team, including members of our team formerly known as Creativ-Ceutical, are looking forward to learning from other industry experts and sharing some of our own research and perspectives.

Here’s where you can find us:
  • Our HEOR and Market Access experts will be sharing posters in dedicated sessions throughout the conference, some in collaboration with clients. Look out for the following titles:

Economic Burden and Quality of Life of Caregivers of Patients with Sickle Cell Disease in the UK and France: A Cross-Sectional Survey

A Methodological Study to Compare Alternative Modes of Administration for Undertaking Preference-Elicitation Studies

Distributional cost-effectiveness analysis of lung cancer treatments from an NHS England perspective

Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients with HR+/HER2-Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours

Cost-Utility Analysis of Avacopan for the Treatment of Anca-Associated Vasculitis (AAV) Patients in the UK

Utilisation of Societal Costs in the NICE HST Approvals Compared to European Agencies

Assessing the Content Validity of Preference-Based Measures in Cancer

Public health impact and cost-effectiveness of empagliflozin (JARDIANCE®) in the treatment of patients with heart failure (HF) with preserved ejection fraction (HFpEF) in France, based on EMPEROR-Preserved clinical trial

Burden and characteristics of COVID-19 in France during 2020 based on national hospital database

A longitudinal study of epidemiology and treatment management of Wilson disease in France based on the French national claims database SNDS

The Burden of Spinal Muscular Atrophy Type 2 (SMA2) on Caregivers in Japan, United Kingdom, and United States: Results of a Global Survey

Public Health Impact and Cost-Effectiveness Analysis of Universal Varicella Vaccination in the United Kingdom

Public Health Impact of COVID-19 in French Ambulatory Patients with at Least One Risk Factor for Severe Disease

Public health impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Ecuador

Public health impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Dominican Republic

Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients With Haemophilia B Without Inhibitors

Fatigue and Health-Related Quality of Life in Paroxysmal Nocturnal Haemoglobinuria

A systematic review of the burden of critical limb ischemia (CLI) among patients with peripheral arterial disease in Japan

Validating the Clinical Utility of Intravascular Ultrasound Guidance during Lower-Extremity Peripheral Vascular Interventions Using Claims Data in Japan from 2009-2020: A Real-World Evidence Study Protocol

  • Podium Presentations:
    P2: The Value of Vaccination: Capturing the Impact of Vaccination on Health Equity in Health Economic Analysis
    Monday, November 7th 10:15-11:15 AM CET
    P33: Use of Real-World Evidence in European Medicines Agency Decisions
    Tuesday, November 8th 11:00-11:15 AM CET
  • Roche Symposium
    134: Inclusion of the Caregiver Perspective in Health Technology Assessment: The Case of Alzheimer’s Disease 
    Monday, November 7th 3-4 PM CET
  • BMS Issue Panel
    141: Not Another Value Framework Extension and Implementation of a Framework to Capture Holistic Value of New Medicines
    Monday, November 7th 4:30 – 5:30 PM CET

We hope to see you there. Please contact us with any questions and learn more about more program details here.

Contact Us